Introduction: Diabetes poses a significant global health challenge, impacting patient well-being and longevity. Despite advances in diagnosis and treatment, the prevalence of diabetes continues to rise, with projections indicating a substantial increase in affected individuals in the coming years. The complications of diabetes, including cardiovascular disease, retinopathy, nephropathy, and neuropathy, underscore the importance of early detection and management. In this context, artificial intelligence (AI) offers promising opportunities to revolutionize diabetes care, enabling faster diagnostics, more effective treatment strategies. Description of the State of Knowledge: Artificial intelligence (AI) has emerged as a transformative force in healthcare, leveraging machine learning and deep learning algorithms to analyze vast amounts of medical data. These algorithms enable more accurate diagnosis, prediction of disease onset, and early detection of complications associated with diabetes. Machine learning models, including support vector machines and neural networks, have shown promise in identifying diabetes risk factors and predicting disease progression. Deep learning techniques, with their ability to analyze complex data patterns, offer further insights into diabetes diagnosis. Additionally, fuzzy cognitive maps provide a framework for decision-making based on patient data, enhancing early detection efforts. Summary: Artificial intelligence holds immense potential to transform diabetes care, offering solutions for early detection, personalized treatment, and improved patient outcomes. By harnessing the power of AI algorithms, healthcare providers can enhance diagnostic accuracy, predict disease progression, and implement targeted interventions.

Multiple myeloma (MM) is a disease caused by the uncontrolled proliferation of clonal plasma cells in bone marrow. Extramedullary plasma cell infiltrations may occur at the time of diagnosis but usually arise during systemic disease progression. Central nervous system (CNS) plasmacytomas are extremely rare (less than 1% of patients with MM) and usually occur as a result of systemic disease progression. The frequency of extramedullary progression to CNS without simultaneous systemic progression is not known. Here, we present a challenging case in which local disease progression to CNS occurred without any signs of systemic progression. The extramedullary plasmacytoma originated from the dura mater of the brain mimicking a brain tumor. We review and discuss further treatment options that are available in such rare clinical scenarios in relation to the treatment already undertaken.

Introduction and objective: In recent years, cases of secondary glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies (ANCA-GN) have been reported following COVID-19 infection or vaccination against SARS-CoV-2. The aim of the study was to analyze publications related to this...

A 2-year-old boy with suspected lactose intolerance developed an extensive, itchy rash after using a nasal spray containing dexpanthenol. He was initially treated for a viral upper airway infection with ibuprofen, xylometazoline, and cetirizine. A switch to a drug containing dexpanthenol led to...

Introduction and aim. Granulomatosis with polyangiitis (GPA), formerly known as Wegener’s granulomatosis, presents a formidable challenge in the realm of autoimmune diseases. Granulomatosis, characterized by vasculitis and granuloma formation, exhibits diverse clinical manifestations. The rarity of GPA is evident, with an estimated incidence between 0.4 and 11.9 cases per 1 million person-years. The aim of this report is to show the complex diagnostic challenges inherent in GPA, demonstrating the diagnostic process from initial symptoms. Description of the case. This case report unfolds the diagnostic journey of a 52-year-old Caucasian male. The presented case, initially suspected as a respiratory infection, led to a comprehensive investigation owing to persistent symptoms, abnormal blood counts, and elevated inflammatory markers. This narrative aims to depict the patient’s diagnostic journey. Key diagnostic tools include ANCA testing, imaging studies, and tissue biopsy. Pulmonary nodules, lymphangitic changes, and renal involvement culminating in a GPA diagnosis confirmed by positive ANCA and anti-PR3 antibodies. The successful management of this case involved a tailored therapeutic regimen, including cyclophosphamide and methylprednisolone, addressing both vasculitic and renal components. Conclusion. This case contributes to the understanding of atypical presentations of GPA, emphasizing the importance of a holistic and dynamic diagnostic approach.

Introduction and purpose: Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare and complex vascular disorder characterized by abnormal blood vessel formation. It can present significant challenges in diagnosis and management, as it is currently estimated up to 90% of those affected are never diagnosed. Despite its rarity, HHT can carry substantial implications for patients and their families, at times requiring comprehensive medical care and support. This paper aims to provide an in-depth exploration of HHT, encompassing its epidemiology, genetics, clinical manifestations, diagnostic approaches, and current management strategies. Moreover, we hope to point out possible areas in need of future research. Description of the state knowledge: HHT is an autosomal dominant genetic disorder that affects 1 in 5-10,000 people. Its most prominent symptoms include telangiectasia of skin and mucous membranes, recurrent epistaxis, gastrointestinal bleeding and arteriovenous malformations in vital organs. In the vast majority of cases, it is caused by a mutation in one of the following genes: ENG, ACVRL1, SMAD4; however, mutations in other genes have been described to cause a similar or much the same constellation of symptoms. Treatment options are focused on managing symptoms and improving quality of life, but possible new treatment options are being researched that could change the landscape of HHT management. Summary: HHT is a severely underdiagnosed disease that has seen a surge of researchers’ interest in recent years. We firmly believe that, combined with plummeting costs of genetic testing and possible new treatment options, means that HHT will become increasingly important in physicians’ everyday practice.